|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker显示文摘 | Richard Morgan Richard T. Bryan Saqib Javed Francesca Launchbury Maurice P. Zeegers K.K. Cheng Nicholas D. James D. Michael A. Wallace Carolyn D. Hurst Douglas G. Ward Margaret A. Knowles Hardev Pandha | 2013 | European Journal of Cancer2013，，9： | 1 |
| 2 | Urinary engrailed‐2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer显示文摘 | Hardev Pandha Karen D. Sorensen Thorsten F. Orntoft Stephen Langley Soren Hoyer Michael Borre Richard Morgan | 2012 | BJU International2012，，6： | 1 |
| 3 | dendritic cell immunotherapy for urological cancers using cryopreserved allogenein tumor lysate-pulsed cell显示文摘 | Pandha Hardev S Menard S | 2004 | BJU International2004，594，3： | 1 |
| 4 | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR‐221&222‐c‐FOS pathway显示文摘 | M. Cristina Errico Federica Felicetti Lisabianca Bottero Gianfranco Mattia Alessandra Boe Nadia Felli Marina Petrini Maria Bellenghi Hardev S. Pandha Marco Calvaruso Claudio Tripodo Mario P. Colombo Richard Morgan Alessandra Carè | 2013 | Int J Cancer2013，，4： | 1 |
| 5 | dendritic cell immunotherapy for urological cancers using cryopreserved allogenein tumor lysate-pulsed cell显示文摘 | Pandha Hardev S Menard S | 2004 | BJU International2004，94，3： | 1 |
| 6 | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR‐221&222‐c‐FOS pathway显示文摘 | M. Cristina Errico Federica Felicetti Lisabianca Bottero Gianfranco Mattia Alessandra Boe Nadia Felli Marina Petrini Maria Bellenghi Hardev S. Pandha Marco Calvaruso Claudio Tripodo Mario P. Colombo Richard Morgan Alessandra Carè | 2013 | Int. J. Cancer2013，，4： | 1 |
| 7 | Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity显示文摘 | Stephen M. Todryk Jonathan Eaton Lindsay Birchall Rebecca Greenhalgh Diane Soars Angus G. Dalgleish Alan A. Melcher Hardev S. Pandha | 2004 | Cancer Immunology Immunotherapy2004，，4： | 1 |
| 8 | Immunoregulatory effects of freeze injured whole tumour cells on human dendritic cells using an in vitro cryotherapy model显示文摘 | Mohamed Ismail Richard Morgan Kevin Harrington John Davies Hardev Pandha | 2010 | Cryobiology2010，，3： | 1 |
| 9 | Individualized therapy for metastatic renal cell carcinoma显示文摘Metastatic Renal Cell Carcinoma(mRCC)is a highly heterogeneous disease that is notoriously difficult to treat successfully.However,the discovery of novel,targeted therapies over the last decade has revolutionized its management.As the therapeutic options continue to evolve,developing a more individualized treatment strategy is of paramount importance.The International mRCC Database Consortium(IMDC)is a prognostic model that is commonly used in trials and clinical settings to risk stratify patients.This allows for optimal therapy selection on a more individual basis.However,the distinct lack of validated predictive biomarkers in mRCC renders it difficult to assess therapy response.An improved understanding of tumor biology and genetics has prompted a shift from cytokine therapy to the use of vascular endothelial growth factor(VEGF)inhibitors,tyrosine kinase Inhibitors,immune checkpoint inhibitors or combination strategies.Studies have identified some putative markers and genetic mutations as potential predictors of therapy response.Early results are promising,and there are many ongoing trials further assessing their suitability for clinical use.This review will evaluate the current treatment landscape and molecular biology of mRCC,with a specific focus on the prognostic and predictive markers available to guide treatment options and further improve patient outcomes. | Bambang T.Atmaja Izabelle Wood Suyanto Suyanto Paramvir Sawhney Agnieszka Michael Hardev Pandha | 2021 | Journal of Cancer Metastasis and Treatment2021，7，1： | 0 |
| 10 | Adjuvant therapy for renal cell carcinoma显示文摘Recent advances in the treatment of metastatic renal cell carcinoma expose a gap in the treatment of less advanced,localized disease.Tyrosine kinase inhibitors,which revolutionized the treatment of metastatic disease,have not provided a similar survival benefit in the adjuvant setting and currently only sunitinib is approved by the Food and Drug Administration for adjuvant treatment in patients with high-risk of recurrence based on S-TRAC disease-free survival data.The advent of immune checkpoint inhibitors has offered a fresh hope in the field of adjuvant treatment after encouraging results are seen with combination of immune checkpoint inhibitors as well as with targeted therapy in the metastatic setting.Several studies are investigating these combinations in the adjuvant setting,and it is hoped that they will bring about a better outcome for a largely unmet need in kidney cancer treatment. | Paramvir Sawhney Suyanto Suyanto Agnieszka Michael Hardev Pandha | 2021 | Journal of Cancer Metastasis and Treatment2021，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员